PTPRC and lung adenocarcinoma: In our previous work (Senosain et al., 2021), we used a panel of antibodies for visualizing of epithelial/tumor cells (PanCK), immune cells (CD45) and T-cells (CD3) (Figure 4A) to reveal relationships between anticancer immune response and behavior (indolent or aggressive) of human lung adenocarcinomas.